Bio-Rad Laboratories (NYSE: BIO) reported earnings on Nov. 6. Here are the numbers you need to know.

The 10-second takeaway
For the quarter ended Sep. 30 (Q3), Bio-Rad Laboratories missed slightly on revenues and crushed expectations on earnings per share.

Compared to the prior-year quarter, revenue shrank and GAAP earnings per share dropped.

Margins dropped across the board.

Revenue details
Bio-Rad Laboratories reported revenue of $498.7 million. The four analysts polled by S&P Capital IQ expected revenue of $508.3 million on the same basis. GAAP reported sales were 3.4% lower than the prior-year quarter's $516.5 million.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
EPS came in at $1.48. The two earnings estimates compiled by S&P Capital IQ forecast $1.14 per share. GAAP EPS of $1.48 for Q3 were 8.1% lower than the prior-year quarter's $1.61 per share.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Margin details
For the quarter, gross margin was 54.8%, 250 basis points worse than the prior-year quarter. Operating margin was 12.9%, 140 basis points worse than the prior-year quarter. Net margin was 8.5%, 40 basis points worse than the prior-year quarter.

Looking ahead
Next quarter's average estimate for revenue is $549.7 million. On the bottom line, the average EPS estimate is $1.25.

Next year's average estimate for revenue is $2.05 billion. The average EPS estimate is $4.99.

Investor sentiment
The stock has a five-star rating (out of five) at Motley Fool CAPS, with 182 members out of 191 rating the stock outperform, and nine members rating it underperform. Among 51 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 51 give Bio-Rad Laboratories a green thumbs-up, and give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Bio-Rad Laboratories is hold, with an average price target of $109.50.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.